@misc{nolan_kent_boss_2019, title={Emerging Translational Opportunities in Comparative Oncology With Companion Canine Cancers: Radiation Oncology}, volume={9}, ISSN={["2234-943X"]}, DOI={10.3389/fonc.2019.01291}, abstractNote={It is estimated that more than 6 million pet dogs are diagnosed with cancer annually in the USA. Both primary care and specialist veterinarians are frequently called upon to provide clinical care that improves the quality and/or quantity of life for affected animals. Because these cancers develop spontaneously in animals that often share the same environment as their owners, have intact immune systems and are of similar size to humans, and because the diagnostic tests and treatments for these cancers are similar to those used for management of human cancers, canine cancer provides an opportunity for research that simultaneously helps improve both canine and human health care. This is especially true in the field of radiation oncology, for which there is a rich and continually evolving history of learning from the careful study of pet dogs undergoing various forms of radiotherapy. The purpose of this review article is to inform readers of the potential utility and limitations of using dogs in that manner; the peer-reviewed literature will be critically reviewed, and current research efforts will be discussed. The article concludes with a look toward promising future directions and applications of this pet dog “model.”}, journal={FRONTIERS IN ONCOLOGY}, author={Nolan, Michael W. and Kent, Michael S. and Boss, Mary-Keara}, year={2019}, month={Nov} }
 @article{boss_dewhirst_sampaio_bennett_tovmasyan_berman_beaven_rizzieri_batinic-haberle_hauck_et al._2017, title={Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy}, volume={80}, ISSN={["1432-0843"]}, DOI={10.1007/s00280-017-3372-z}, abstractNote={Manganese porphyrins are redox-active drugs and superoxide dismutase mimics, which have been shown to chemosensitize lymphoma, a cancer which frequently occurs in dogs. This study aimed to identify critical information regarding the pharmacokinetics and toxicity of Mn(III) meso-tetrakis (N-n-butoxyetylpyridium-2-yl) porphyrin, (MnTnBuOE-2-PyP5+, MnBuOE) in dogs as a prelude to a clinical trial in canine lymphoma patients. A single-dose pharmacokinetic (PK) study in normal dogs was performed to determine the plasma half-life (t 1/2) of MnBuOE. A dose reduction study was performed to establish the maximum tolerated dose (MTD) of MnBuOE. The safety and PK of a multi-dosing protocol was assessed. Peak plasma drug concentration occurred 30 min post-injection. The t 1/2 was defined as 7 h. MnBuOE induced an anaphylactic reaction and prolonged tachycardia. The MTD was defined as 0.25 mg/kg. The dogs were given MTD 3×/week for 2–3 weeks. The highest recorded tissue drug levels were in the lymph nodes (4–6 μM), followed by kidney and liver (2.5, 2.0 uM, respectively). We obtained critical information regarding the PK and toxicity of MnBuOE in dogs. The acute drug reaction and tachycardia post-injection have not been described in other species and may be specific to canines. The high tissue drug levels in lymph nodes have not been previously reported. MnBuOE accumulation in lymph nodes has important implications for the utility of adjuvant MnBuOE to treat lymphoma. With MnBuOE lymph node accumulation, reduction in the dose and/or administration frequency could be possible, leading to reduced toxicity.}, number={2}, journal={CANCER CHEMOTHERAPY AND PHARMACOLOGY}, author={Boss, M. K. and Dewhirst, M. W. and Sampaio, R. S. and Bennett, A. and Tovmasyan, A. and Berman, K. G. and Beaven, A. W. and Rizzieri, D. A. and Batinic-Haberle, I. and Hauck, M. L. and et al.}, year={2017}, month={Aug}, pages={421–431} }
 @article{boss_dewhirst_2015, title={A tribute to Philip Marcus and the development of the clonogenic assay}, volume={183}, number={5}, journal={Radiation Research}, author={Boss, M. K. and Dewhirst, M.}, year={2015}, pages={497–500} }
 @article{tovmasyan_sampaio_boss_bueno-janice_bader_thomas_reboucas_orr_chandler_go_et al._2015, title={Anticancer therapeutic potential of Mn porphyrin/ascorbate system}, volume={89}, journal={Free Radical Biology & Medicine}, author={Tovmasyan, A. and Sampaio, R. S. and Boss, M. K. and Bueno-Janice, J. C. and Bader, B. H. and Thomas, M. and Reboucas, J. S. and Orr, M. and Chandler, J. D. and Go, Y. M. and et al.}, year={2015}, pages={1231–1247} }
 @article{fontanella_boss_hadsell_zhang_schroeder_berman_dewhirst_chang_palmer_2015, title={Effects of high-dose microbeam irradiation on tumor microvascular function and angiogenesis}, volume={183}, number={2}, journal={Radiation Research}, author={Fontanella, A. N. and Boss, M. K. and Hadsell, M. and Zhang, J. and Schroeder, T. and Berman, K. G. and Dewhirst, M. W. and Chang, S. and Palmer, G. M.}, year={2015}, pages={147–158} }
 @misc{lee_boss_dewhirst_2014, title={Imaging tumor hypoxia to advance radiation oncology}, volume={21}, number={2}, journal={Antioxidants & Redox Signaling}, author={Lee, C. T. and Boss, M. K. and Dewhirst, M. W.}, year={2014}, pages={313–337} }
 @misc{boss_bristow_dewhirst_2014, title={Linking the history of radiation biology to the hallmarks of cancer}, volume={181}, number={6}, journal={Radiation Research}, author={Boss, M. K. and Bristow, R. and Dewhirst, M. W.}, year={2014}, pages={561–577} }
 @article{boss_muradyan_thrall_2013, title={DCE-MRI: a review and applications in veterinary oncology}, volume={11}, ISSN={["1476-5829"]}, DOI={10.1111/j.1476-5829.2011.00305.x}, abstractNote={Abstract}, number={2}, journal={VETERINARY AND COMPARATIVE ONCOLOGY}, author={Boss, M. Keara and Muradyan, N. and Thrall, D. E.}, year={2013}, month={Jun}, pages={87–100} }
 @article{boss_2007, title={History}, volume={230}, ISSN={["0003-1488"]}, DOI={10.2460/javma.230.7.995}, number={7}, journal={JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION}, author={Boss, Mary-Keara}, year={2007}, month={Apr}, pages={995–996} }